Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential f
Storage Temp
Protected from light,Store at -20°C
Shipped In
Ice chest + Ice pads
Product Description
Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .
In Vitro
Masoprocol (30 µM; 90 min) shows high basal and insulin-stimulated glucose clearance in adipocytes. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Masoprocol (150 mg/kg; i.g.; twice a day for 12 days) shows antihyperglycemic activity with the decreases in glucose concentration in plasma in male C57BL/ks-db/db mice .\nMasoprocol （0.83 mmol/kg; twice a day for 4 days）shows low glucose concentrations an average of 35% and low triglyceride concentrations of 80% compared with the vehicle at a rat model of type II diabetes.\nMasoprocol (40-80 mg/kg; p.o.; twice daily for 8 days) significantly reduces hepatic triglyceride (TG) secretion (P
Form:Solid
Product Properties
ALogP
4.3
Associated Targets
CTNNBIP1Tbio Beta-catenin-interacting protein 1 0 Activities
